Related Experiment Video
Updated: Jul 3, 2026

Primary Cultures of Rat Astrocytes and Microglia and Their Use in the Study of Amyotrophic Lateral Sclerosis
Published on: June 23, 2022
SGK1-mediated deficits in microglial phagocytosis drive pathological progression in amyotrophic lateral sclerosis
Meijun He1, Chaoran Wu1,2, Mengqiu Hu1
1New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China.
Abstract:
Alterations in microglial function and transcriptomic profiles are major pathological hallmarks of amyotrophic lateral sclerosis (ALS). However, the dynamics and regulatory mechanisms underlying microglial phagocytic activity during disease progression remain unclear. In this study, we observed stage-dependent alterations in microglial phagocytic activity during disease progression in SOD1G93A mice. Single-cell RNA sequencing suggested that this change was associated with a reduced abundance of microglial subpopulations enriched for phagocytosis-related pathways. Transcriptomic analysis identified serum- and glucocorticoid-regulated kinase 1 (SGK1) as a potential mediator of this process. Notably, sgk1 knockout in SOD1G93A mice was associated with improved microglial clearance of myelin debris and reduced aberrant engulfment of neuronal material after disease onset. Our results further showed that, after disease onset, the accumulation of myelin debris and apoptotic neurons induced SGK1 upregulation in microglia from SOD1G93A mice. Mechanistically, SGK1 appeared to promote lipid accumulation in microglia by suppressing lipophagy, thereby impairing the ability of microglia to clear cellular debris. Moreover, pharmacological inhibition of SGK1 with GSK650394 attenuated motor deficits and prolonged survival in SOD1G93A mice. Together, our findings provide evidence for a previously unrecognized role of SGK1 in regulating microglial phagocytosis in ALS models and support SGK1 as a potential therapeutic target in SOD1 mutation-associated ALS models.
Insights
Amyotrophic lateral sclerosis (ALS) involves altered microglial phagocytosis. This study reveals serum- and glucocorticoid-regulated kinase 1 (SGK1) impairs microglial debris clearance in ALS mice, suggesting SGK1 as a therapeutic target.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Microglial dysfunction is a key feature of amyotrophic lateral sclerosis (ALS).
- The precise mechanisms regulating microglial phagocytosis during ALS progression are not fully understood.
Purpose of the Study:
- To investigate the dynamics of microglial phagocytic activity in ALS models.
- To identify molecular regulators of microglial phagocytosis in ALS.
- To evaluate SGK1 as a potential therapeutic target for ALS.
Main Methods:
- Utilized SOD1G93A mouse models of ALS.
- Performed single-cell RNA sequencing and transcriptomic analysis.
- Investigated the effects of SGK1 knockout and pharmacological inhibition (GSK650394).
Main Results:
- Microglial phagocytic activity changed with disease stage in SOD1G93A mice.
- SGK1 was identified as a key regulator, suppressing microglial clearance of debris and promoting lipid accumulation by inhibiting lipophagy.
- SGK1 knockout or inhibition improved debris clearance, reduced neuronal engulfment, attenuated motor deficits, and prolonged survival.
Conclusions:
- SGK1 plays a critical role in impairing microglial phagocytosis in ALS.
- Targeting SGK1 offers a promising therapeutic strategy for SOD1 mutation-associated ALS.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Alzheimer Disease ll: Pathophysiology
Myasthenia Gravis ll: Pathophysiology

